Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03719326
Title A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Arcus Biosciences, Inc.

triple-receptor negative breast cancer

ovarian cancer


AB928 + IPI-549 + Pegylated liposomal-doxorubicin

AB928 + Pegylated liposomal-doxorubicin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.